RJA
NYMX

Raymond James & Associates’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Raymond James & Associates’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,960
Closed -$51K – 3455
2017
Q1 		$51K Buy
+13,960
New +$45.9K ﹤0.01% 3141

Other funds holding NYMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James & Associates's NYMX Position: Q2 2017 in Review

Raymond James & Associates sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2017, closing a stake of 13,960 shares — an estimated $51K sold.

Raymond James & Associates first reported a position in NYMX in Q1 2017 and held it in 1 quarter. The position peaked at $51K in Q1 2017. 45 funds tracked by Wall St. Rank hold NYMX as of Q2 2017.

  • Raymond James & Associates reported no remaining Nymox Pharmaceutical Corp position as of Q2 2017 after selling out during the quarter.
  • Raymond James & Associates sold 13,960 Nymox Pharmaceutical Corp shares in Q2 2017, an estimated $51K.
  • Raymond James & Associates first reported a position in Nymox Pharmaceutical Corp in Q1 2017 and held it in 1 quarter.
  • Raymond James & Associates's Nymox Pharmaceutical Corp position peaked at $51K in Q1 2017.
  • 45 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2017.

Based on Raymond James & Associates's 13F filing for Q2 2017, filed 14 Aug 2017.